DYAI — Dyadic International Inc

Dyadic International Inc (DYAI) is a biotechnology company listed on NASDAQ. It is led by Mark A. Emalfarb, based in 1044 North U.S. Highway One, Jupiter, FL, United States, 33477-5094, with about 5 employees. Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Latest reported DYAI revenue for 2025-09-30 was $1.2M. Net income was -$2.0M. Revenue was up 20.5% from 2025-06-30 to 2025-09-30. DYAI currently screens at market cap $25.9M.

Use this DYAI page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the DYAI quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the DYAI SEC filings page. Lician reads the product cache first so this HTML stays unique to Dyadic International Inc even when a live quote feed is slow.